Modality
Fusion Protein
MOA
IL-13i
Target
TYK2
Pathway
Notch
PTSDDravet
Development Pipeline
Preclinical
~Aug 2013
→ ~Nov 2014
Phase 1
~Feb 2015
→ ~May 2016
Phase 2
~Aug 2016
→ ~Nov 2017
Phase 3
Feb 2018
→ Sep 2031
Phase 3Current
NCT07250649
931 pts·Dravet
2021-07→2026-02·Recruiting
NCT04553400
1,722 pts·PTSD
2020-04→2025-01·Recruiting
NCT07975875
2,211 pts·PTSD
2018-02→2031-09·Completed
4,864 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-01-131.2y agoPh3 Readout· PTSD
2026-02-062mo agoPh3 Readout· Dravet
2031-09-185.5y awayPh3 Readout· PTSD
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Complet…
P3
Recruit…
P3
Recruit…
Catalysts
Ph3 Readout
2025-01-13 · 1.2y ago
PTSD
Ph3 Readout
2026-02-06 · 2mo ago
Dravet
Ph3 Readout
2031-09-18 · 5.5y away
PTSD
RecruitingCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07250649 | Phase 3 | Dravet | Recruiting | 931 | BodyWt |
| NCT04553400 | Phase 3 | PTSD | Recruiting | 1722 | OS |
| NCT07975875 | Phase 3 | PTSD | Completed | 2211 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 |